ST6GAL1 Rabbit anti-Human, Polyclonal, Invitrogen
Rabbit Polyclonal Antibody
Manufacturer: Invitrogen PA527982
PA5-27982 targets CD75 in IHC (P) and WB applications and shows reactivity with Human samples. The PA5-27982 immunogen is recombit fragment corresponding to a region within amino acids 100 and 387 of Human CD75. Store product as a concentrated solution. Centrifuge briefly prior to opening the vial. For short-term storage (1-2 weeks), product can be stored at 4°C. For long-term storage, aliquot and store product at -20° C or below, avioiding multiple freeze-thaw cycles.The protein encoded by this gene is a type II membrane protein that catalyzes the transfer of sialic acid from CMP-sialic acid to galactose-containing substrates. The encoded protein, which is normally found in the Golgi but which can be proteolytically processed to a soluble form, is involved in the generation of the cell-surface carbohydrate determits and differentiation antigens HB-6, CDw75, and CD76. This protein is a member of glycosyltransferase family 29. Three transcript variants encoding two different isoforms have been found for this gene.
|Recombit fragment corresponding to a region within amino acids 100 and 387 of Human CD75|
|Antigen affinity chromatography|
|Immunohistochemistry (Paraffin), Western Blot|
|0.1M tris glycine with 10% glycerol and 0.01% thimerosal; pH 7|
|Sialyltransferase 1, SIAT1, ST6GalI, ST6N, B-cell antigen CD75, CMP-N-acetylneuraminate beta-galactosamide alpha-2, 6-sialyltransferase, CMP-N-acetylneuraminate-beta-galactosamide-alpha-2, 6-sialyltransferase 1, ST6Gal I, alpha 2, 6-ST 1, beta-galactoside alpha-2, 6-sialyltransferase 1, sialyltransferase 1|
|Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok